US signs $1.2 bn deal for 1.7 mn courses of Merck’s experimental Covid-19 drug

Read Time:1 Minute, 31 Second

Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment if it is proven to work in an ongoing large trial and authorized by U.S. regulators.

The oral antiviral treatment, molnupiravir, aims to stop COVID-19 from progressing and can be given early in the course of the disease, similar to Tamiflu to treat influenza.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %